Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders - Seite 2

Highlights from Dr. Schilling’s presentation include:

• Pyroglutamate-modified Abeta (N3pE-Abeta) is a trigger of toxicity in AD and there is a strong rationale for targeting N3pE-Abeta to create a tailored AD therapy.
• Experimental data show that N3pE-Abeta has very different physio-chemical properties compared to other Abeta variants, including its potential to form highly toxic oligomers and fibrils together with non-modified Abeta variants.
• Strong pre-clinical evidence supports the hypothesis that reducing N3pE-Abeta formation by inhibiting the enzyme QPCT, has the potential to change the course of progression of AD.
  
  

Highlights from Dr. Harrison’s presentation include:

• AD is a disorder of cognition, not just memory and MCI and early AD are characterized by a variety of cognitive deficits.
• The Cogstate NTB, which is used to assess the effect of varoglutamstat on cognition in the primary and secondary endpoints in the VIVIAD study, is a sensitive and well-established scale in the field of AD research. It has the advantage of investigating a broad range of cognitive domains acknowledged to be clinically meaningful measures of function.
• A preliminary blinded data analysis (cut-off May 2023) conducted for the Data Safety Monitoring Board (DSMB) showed that the trajectory of the Cogstate Brief Battery (CBB, which includes Identification, Detection, One Back, and One Card Learning of the NTB) in VIVIAD displayed a ~28% change from baseline (n= >250 patients) compared to the end of treatment (week 96 or early discontinuation of treatment; n=36 patients at data cut-off).
• Within this preliminary blinded analysis, the four individual test components of the CBB (Identification, Detection, One Back, One Card Learning) displayed declines that varied in trajectories, supporting the concept that patients with early AD have variable progression rates for individual memory functions. While these preliminary data support the selection of the Cogstate NTB as primary and key secondary endpoints in VIVIAD to assess the effect of varoglutamstat on cognition, it is important to note that no assessment of the efficacy of varoglutamstat can be derived from this preliminary and blinded dataset.

Highlights from Dr. Sikkes’ presentation include: